FDA 483 - Eric T. Rush M.D - October 24, 2025

An FDA inspection of Eric T. Rush M.D. in Kansas City, MO, revealed significant deficiencies in the conduct of clinical trials. Observations included failure to follow investigational plans, such as missed study visits, unperformed study activities, delayed reporting of serious adverse events, and inadequate documentation of adverse events. Additionally, the firm experienced a lapse in IRB approval for a clinical study due to untimely submission of required documentation.